Abstract Number: 2583 • 2016 ACR/ARHP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). A potential association of anti-TNFα drugs and conventional disease-modifying anti-rheumatic drugs…Abstract Number: 2584 • 2016 ACR/ARHP Annual Meeting
Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs
Background/Purpose: Anemia in rheumatoid arthritis (RA) patients (pts) has a prevalence of 16%-64% depending on population and severity of disease1,2,3 and is more common…Abstract Number: 2585 • 2016 ACR/ARHP Annual Meeting
Serum MMP-3 and OPG As Predictors of Response to Traditional Dmards in a Treatment NaïVe Early Rheumatoid Arthritis Cohort
Background/Purpose: Bone and cartilaginous metabolites such as matrix metalloproteinase 3 (MMP-3), cartilage oligomeric matrix protein (COMP),receptor activator for nuclear factor κ B ligand (RANKL) and…Abstract Number: 2586 • 2016 ACR/ARHP Annual Meeting
Comparison of Intra-Articular Methylprednisolone Acetate with Triamcinolone Acetonide in Acutely Swollen Knee Joint of Patients with Chronic Inflammatory Arthritis – a Randomized Controlled Trial
Background/Purpose: Intra-articular steroids are in use since half-a-century, but choice of individual agents remains empirical in the absence of comparative trials. This study compared the…Abstract Number: 2587 • 2016 ACR/ARHP Annual Meeting
The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…Abstract Number: 2588 • 2016 ACR/ARHP Annual Meeting
The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort
Background/Purpose: To examine the association of cardiovascular, malignant and serious infection events (SIEs) with certolizumab pegol (CZP) use as compared to other TNFi agents in…Abstract Number: 2589 • 2016 ACR/ARHP Annual Meeting
Comparison of Two Enzyme-Linked Immunosorbent Assays Used for Drug Concentration Monitoring in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Measurement of plasma anti-TNF concentration, in combination with the assessment of clinical outcomes, may be used to optimize dosing regimens for individual patients (pts).…Abstract Number: 2590 • 2016 ACR/ARHP Annual Meeting
The Efficacy of Additional Immunoadsorption on the Modulation of Disease Activity in Patients with Severe Rheumatoid Arthritis
Background/Purpose: Immunoadsorption been used in patients with severe refractory rheumatoid arthritis (RA) was first reported in 1994, and the efficacy is promising. However, the subset…Abstract Number: 2591 • 2016 ACR/ARHP Annual Meeting
Association Between Flare and Radiographic Progression in Patients with Rheumatoid Arthritis
Background/Purpose: Biologic therapy has improved RA management and enabled some patients to achieve remission. Many clinicians decrease the biologic dose for patients in low disease…Abstract Number: 2592 • 2016 ACR/ARHP Annual Meeting
The Impact of Biologic Therapy Introduction on Hip and Knee Replacement Among Rheumatoid Arthritis Patients: An Interrupted Time Series Analysis Using the Clinical Practice Research Datalink
Background/Purpose: In several developed countries it has been observed that the incidence of orthopaedic surgery among rheumatoid arthritis (RA) patients has been in decline, despite…Abstract Number: 2593 • 2016 ACR/ARHP Annual Meeting
The Effect of Tofacitinib on Bone Mineral Density in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
Background/Purpose: To analyze the effects of therapy with tofacitinib (Tofa), a Janus kinase inhibitor on the bone mineral density (BMD) of the lumbar spine and…Abstract Number: 2594 • 2016 ACR/ARHP Annual Meeting
Physician/Site Staff Assessments Contribute to High Placebo Response in Rheumatoid Arthritis Clinical Trials
Background/Purpose: High ACR responses in placebo group have been frequently observed in recent RA trials, most notably, in patients with inadequate response (IR) to methotrexate…Abstract Number: 2595 • 2016 ACR/ARHP Annual Meeting
Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry
Background/Purpose: An interim analysis of a prospective observational 3+ year study, embedded within the US Corrona Rheumatoid Arthritis (RA) registry (14 years and ongoing), was…Abstract Number: 2596 • 2016 ACR/ARHP Annual Meeting
Comparable Safety and Immunogenicity and Sustained Efficacy after Transition to SB2 (An Infliximab Biosimilar) Vs Ongoing Reference Infliximab (Remicade®) in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study
Background/Purpose: SB2 is approved by the European Medicines Agency as a biosimilar of the reference infliximab (INF). The 30-week and 54-week results of Phase III…Abstract Number: 2597 • 2016 ACR/ARHP Annual Meeting
Time to Initiation of Biologic Agents Is Associated with Glucocorticoid Use: Results from the Corrona Registry
Background/Purpose: Despite new effective therapies for Rheumatoid Arthritis (RA), glucocorticoids (GC) are widely prescribed. It is possible that dose and duration of GC therapy may…
ACR Meeting Abstracts